Letter: Novel Renoprotective Mechanisms of PCSK9 Inhibitors: Lipid-Lowering,Anti-Inflammation,and Gut-Kidney Axis Modulation

Abstract

Get full access to this article

View all access options for this article.

References

Zha

Fan

, et al. Protective effects of PCSK9 inhibitors on renal function in ASCVD patients at high risk for contrast-associated acute kidney injury. Angiology. 2025.

Delialis

Dimopoulou

Papaioannou

, et al. PCSK9 inhibition in atherosclerotic cardiovascular disease. Curr Pharm Des. 2023;29:1802-1824.

Cheng

Zhan

Yuan

, et al. Boeravinone C ameliorates lipid accumulation and inflammation in diabetic kidney disease by activating PPARα signaling. J Ethnopharmacol. 2025;342:119398.

Zhang

Zhu

Gao

Xing

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge. Front Pharmacol. 2023;14:1291922.

De Maeyer

RPH

van de Merwe

Louie

, et al. Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. Nat Immunol. 2020;21:615-625.

Liu

Stolarz

, et al. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging. Theranostics. 2023;13:2914-2929.

Baginski

Farmer

Baumer

Wallen

Powell-Wiley

TM.

Interleukin-8 (IL-8) as a Potential Mediator of an Association between Trimethylamine N-Oxide (TMAO) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) among African Americans at Risk of Cardiovascular Disease. Metabolites. 2022;12:1196.

Koren

Lundqvist

Bolognese

, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531-2540.